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Research questions: Couples undergoing IVF in
Switzerland may have embryos in excess of their
clinical need that they can donate to human em-
bryonic stem cell research. Thus a new practice
has emerged in Switzerland when IVF treatment
and embryonic stem cell research come into con-
tact. This interface needs to be investigated from
an ethical-legal point of view to facilitate a fair in-
formed choice process for the couples involved.
Methods: Ethical analysis, patient perspectives
elaboration. Interdisciplinary approach that draws
on the research project JESP-ELSI (joint embry-
onic stem cell research project – ethical legal and
societal implications). 
Results and conclusions: To facilitate the dona-
tion of surplus embryos to human embryonic
stem cell research, we propose a procedure of in-
formed choice that fits to the current Swiss legal
situation. In addition we identify problems within
the current legal setting and suggest methods to
improve communication at the interface between
IVF and embryonic stem cell research from an
ethical perspective.
Key words: bioethics; patient perspective; embryo
donation; informed consent; hESC research; Switzer-
land
Summary
In Switzerland, the practice of conducting
human embryonic stem cell (hESC) research with
donated surplus embryos from in vitro fertiliza-
tion (IVF) clinics began in 2005 within the legal
framework of a new Stem Cell Research Act [1].
Initial practical experience with this framework
can now be examined in an accompanying study
of the ethical, legal and social implications of the
law1. This is still a novel process for all involved
parties: the stem cell researchers, the IVF special-
ists, the obstetrical care teams and, of course, the
couples undergoing IVF, who might be asked to
donate a surplus embryo to hESC research. They
are all confronted with a variety of ethical issues
and legal challenges, some of them already known
from other contexts, but others without prece-
dents. Thus “embryo donation” is a new social
function that has only emerged within the setting
of assisted reproduction at the interface of IVF
treatment and hESC research [2]. 
The practical interrelations at the IVF-hESC
interface (between the therapeutic context of re-
productive medicine and the sourcing of embryos
for stem cell research) have produced a zone of
potential conflicts of interest around the produc-
tion and fate of embryos [3]. Some authors argue
against the donation of fresh embryos at all [4] on
the grounds that, if the treating physicians have
an interest in producing surplus embryos for stem
cell laboratories, they cannot be described as
working exclusively in the best interest of their
patients, who want to use the embryos for preg-
nancy [5]. The legislator was aware of this poten-
tial conflict of interest when Art. 6 of the Stem
Cell Research Act were drafted. This article al-
ready requires a strict separation between persons
involved in the assisted reproduction procedure
and those involved in the derivation of stem cells.
In general, the Swiss Stem Cell Research Act was
drafted within a discursive climate of embryo pro-
tection and includes safeguards to prevent the in-
tentional production of a spare embryo [2, 6].
However, less attention was given to the situation
experienced by the couples [7, 10]. In our study,
we focused on the experience and the perspective
of IVF couples having one or several spare em-
bryos that could be donated to hESC research.
Our research combined qualitative, legal and eth-
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ical approaches. Elsewhere we have reported on
the moral perception of the embryo by patients
undergoing IVF, comparing Switzerland and the
UK [10]. One part of our research was aimed at
helping to establish an appropriate informed
choice procedure for donation of spare embryos
to hESC research. This required an international
comparison of informed consent procedures [9].
A major part of our work, however, involved iden-
tifying legal issues that emerged in practice at the
rapidly developing IVF-hESC interface in the
Swiss context [8]. The present paper focuses on
the requirements of a sound informed choice pro-
cedure within the given legal setting.
Since the Federal Stem Cell Research Act
came into force in 2005, hESC research has been
explicitly regulated in Switzerland. Under certain
strictly defined conditions it is permissible to use
‘surplus embryos’ from IVF treatments to derive
human stem cell lines. Embryos become surplus
(or spare, supernumerary) in the sense of the law
if they cannot be transferred to the woman’s
uterus in IVF treatment, for reasons of embryo
morphology (poor quality embryos), or because
of medical or other considerations which are inde-
pendent of the aims of hESC research [11]. How-
ever, such surplus embryos are rare. The Federal
Act on Reproductive Medicine – concretising Art
119. of the Swiss constitution – restricts the num-
ber of embryos developed in vitro to three per
IVF cycle, and in principle all must be transferred
to the uterus. Thus the occurrence of a surplus
embryo is the exception rather than the rule
within the regime of IVF treatment in Switzer-
land. Researchers conducting hESC research also
need to prove that the research goals are valuable,
and must apply for a licence for hESC derivation
from the Swiss Federal Office of Public Health.
This level of oversight aims to ensure that no
human embryos are wasted. 
Feki et al. [12] used surplus embryos that had
been cryopreserved prior to 2001. Before the
Federal Act on Reproductive Medicine came into
force in Switzerland in 2001, cryopreservation of
embryos was allowed. Under certain conditions,
stem cell researchers may use these surplus em-
bryos cryopreserved prior to 2001 for research
purposes. Embryos that are spare in the sense of
the current law may not be cryopreserved, but
neither can they be used for deriving stem cells
after their seventh day of development (Art. 17
para 3 Federal Act on Reproductive Medicine,
Art. 3 para 2 lit. c Federal Stem Cell Research
Act). Therefore, the decision time available to a
couple who know they have a surplus embryo is
very short. Our results from qualitative interviews
with couples, who were asked to donate these cryo -
preserved surplus embryos to hESC research [10],
show that the period of time between IVF (and
freezing) and the actual request is a significant
factor in their situation. These former IVF pa-
tients know whether their IVF was ultimately
 successful, information that cannot be known by
patients in a current IVF cycle who are asked to
donate ‘fresh’ embryos. The experience of former
IVF patients who receive a request for donation
from their IVF clinics long after their treatment is
completed, is therefore not directly comparable
to that of patients who are asked within ongoing
IVF cycles to donate fresh surplus embryos. 
The patient point of view – Couples at the
 interface between IVF and hESC research 
In the current Swiss legal setting, IVF doctors
must inform the couples about the possibility of
being asked to donate a surplus embryo to stem
cell research, if this option arises concretely
within an ongoing IVF cycle. But timing is criti-
cal. When such surplus embryos originate in on-
going IVF cycles, they are referred to as “fresh”
surplus embryos. They can either be donated for
hESC research or couples may decide to have
them destroyed. A third option does not exist due
to current Swiss prohibitions on cryopreservation
of embryos and on donation for any purpose
other than stem cell research. From an ethical
point of view, the management of this process is
not easy.
The ethical-legal issues of the choices avail-
able to patients at the IVF-hESC interface are
under discussion in many countries [13]. Some of
the international discussion focuses on comparing
the policy approaches to hESC research [14],
while a vast bioethical literature focuses on the
moral status of the embryo in general [15–18].
The international debate agrees on one crucial
point: within the options that are possible legally
and biologically, the responsibility for deciding
what will happen to their spare embryos rests
with the couple. 
From this point of view, some major ethical
questions arise. Can couples decide to give sur-
plus embryos to research while at the same time
still trying to achieve pregnancy? How can this
decision be best supported within an ethically
sound process of informed choice? Can couples
really understand their own role at the interface
between IVF treatment and research? Is there a
risk that they might be (or perceive themselves to
be) exploited by giving away some of the ‘pre-
cious’ entities (the surplus embryo) that might in
other circumstances have resulted in babies to re-
search? These questions are not purely ethical
ones, because the answers must be implemented
within the existing legal settings.  
552A challenged choice: donating spare embryos to stem cell research in Switzerland
551-556 Porz 12420.qxp  9.9.2008  14:41 Uhr  Seite 552
553
The role of the couple in the donation
process 
From a sociological point of view, a new role
has been created in this interface: the “embryo
donor” [2]. This new social role comes with new
practical possibilities and moral responsibilities
and influences the ‘identity’ (or the self-image) of
patients in reproductive medicine. Symbolically
and legally, this is expressed in the organization
and performance of an informed consent proce-
dure. As the word ‘consent’ presupposes accept-
ance we find it more appropriate to speak of an
‘informed choice process’ to indicate that the
couple has the possibility of deciding the fate of
their surplus embryos. Couples need to under-
stand the choice with which they are confronted,
and that they should freely decide either for do-
nation, if they wish to have their surplus embryos
used in hESC research or for destruction of the
embryo if they do not. 
Two additional questions arise at the very
outset of the process: Do couples consider the
practice that they are asked to decide on as a ‘do-
nation’ ie as a gift, or as a ‘giving away’ of the
 embryo? And is the establishment of stem cell
lines seen as just another way of ‘destroying’ their
embryo? The patients’ understanding of the prac-
tice is likely to be significantly different according
to whether they think: “I gave away my surplus
embryo to research”, “I donated my surplus em-
bryo to research”, or “My embryo was destroyed
and used for research”. The language used may
change the context, trigger certain decisions or
favour one choice over another. For example, ‘do-
nation’ is generally considered to be a good thing
to do. There are analogies to blood, tissue, organ,
sperm or egg donation. However, embryo dona-
tion cannot easily be compared with such other
forms of donation, because the embryo with its
potential for development is a unique entity and
not comparable with other body parts that lack
such a potential. Both IVF doctors and stem cell
researchers need to take this into account. 
As far as we can judge, no coherent linguistic
practice has yet been established in this area.
However, promoting the exclusive use of scien-
tific language (zygote, blastomere, blastocyst etc.)
would hardly be a solution. The ontological and
moral status is an issue when it comes to decide
upon the research use of an embryo that once car-
ried the hopes of the couple for children. A seem-
ingly neutral objective scientific vocabulary is on-
tologically not neutral, because it suggests that
those entities are nothing but cells developing.
Scientific language, in this context, is therefore
not morally neutral. 
Understanding the current legal setting 
A key point of contention lies in the precise in-
terpretation of what the law permits in terms of in-
forming patients and requesting consent to donate.
Article 5 para 1 of the Stem Cell Research Act de-
termines that a surplus embryo ‘may only be used
for the derivation of embryonic stem cells if writ-
ten consent has been freely given by the couple
concerned’. Before such consent is given, the cou-
ple is to be provided with adequate information,
verbally and in writing, in a comprehensible form,
concerning the use of the embryo. Para 2 then
holds that a “request [for donation] may only be
made to the couple after the determination of the
surplus status of the embryo.” The Ordinance on
Stem Cell Research, moreover, stipulates in Article
2 para 4 that the couple must be given enough time
to take their decision. However, Art. 17 para 2 of
the Federal Act on Reproductive Medicine limits
this time indirectly, when it states that an embryo
in vitro can only be developed to the stage at which
nidation (implantation into the uterine lining)
would occur in vivo. Cryopreservation of the sur-
plus embryo at this stage is forbidden. 
Thus a complex grid of regulations results in
a very narrow timeframe during which the couple
must: (i) be informed that an embryo has become
surplus, and why; (ii) be informed about the alter-
natives of donating this embryo to stem cell re-
search or of having it destroyed (or allowed to
die); (iii) undertake their considerations; and fi-
nally (iv) take a decision about the surplus em-
bryo. One possible interpretation of the law is
that patients may not be told about the possibility
that a surplus embryo will arise until it does so,
and if so steps (i) to (iv) might be difficult to com-
plete in the short time of one to two days that is
effectively produced by the combination of biol-
ogy and the law.
However, the legislator is likely to have been
aware of these constraints and another interpreta-
tion is more evident. The official commentary to
the draft of the Stem Cell Research Act explains
the regulation of the time point at which the re-
quest can be made (Art. 5 para 2, see above). Ac-
cording to the commentary this provision states
that no request for donation should be made dur-
ing the IVF procedure, at least until it is clear that
an embryo has become surplus, in order not to in-
fluence the process of IVF [19]. The Ordinance
on Stem Cell Research substantiating the Act on
Stem Cell Research reinforces this timing in Arti-
cle 1, when it requires the doctor to inform the
couple that an embryo has become surplus, to-
gether with the reasons why and the conse-
quences [20]. The commentary to the Ordinance
states that the timing of the request is important
in order to ensure the separation between IVF
treatment and research. The couple should never
find themselves in a situation in which they would
have to decide between the use of an embryo for
reproductive purposes on the one hand or for re-
search purposes on the other [21].
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However, the surplus embryo may also be
considered as a ‘side-effect’ of IVF and the couple
must be informed about all the potential risks of
IVF before they can give their informed consent
to this treatment. One risk is that an embryo, for
one reason or another, cannot be transferred. It is
imaginable that a couple might reject IVF treat-
ment because they do not want to find themselves
in a situation in which they would have to take a
decision about a surplus embryo. Our conclusion
is therefore that the law may be interpreted such
that (i) couples should at least be informed about
the possible need for a future decision in those ex-
ceptional cases when a surplus embryo is pro-
duced by their treatment, but that (ii) there is no
room within the law for systematically informing
the couple about the concrete possibilities of dona-
tion to stem cell research. This option can only be
explained later when a surplus embryo has actu-
ally been produced. From the viewpoint of the
current law, the concrete request to use a surplus
embryo for hESC research cannot be made be-
fore it is clinically clear that the embryo is surplus. 
The ethical complexity of informed choice
We have also drawn up an international com-
parison of guidelines for embryo donation to
hESC research. The comparison was carried out
to identify the most important elements that
should be taken into account in developing an
ethically sound informed choice procedure. 
Thus we have analysed and compared 39
 documents developed by governmental bodies,
national bioethics committees, ad hoc advisory
groups and national institutes of research in vari-
ous countries that allow procurement of hESC
from surplus embryos. Other documents by inter-
national organisations dealing with ethical issues
of hESC research have also been considered.
While keeping in mind that different national
legal settings allow variations in the conduct of
the informed choice process, a comparison of
these documents has allowed us to identify a
framework of three key elements for an ethically
sound informed choice for embryo donation to
stem cell research [9]: who, what and when. 
(1) “Who?” – an informed choice procedure
must specify who should give consent and who
should obtain consent. (2) “What?” – it must also
define what kind and amount of information
should be provided to donors. (3) “When?” – it
must be clear about the point at which informed
consent (or non-consent) should be obtained and
define the proper time schedule for the overall in-
formed choice procedure.
The relevance of these three elements is sub-
stantiated by the literature on the ethics of em-
bryo donation to stem cell research, in particular
by Lo et al. [22].
In terms of the “who” element, all the docu-
ments investigated emphasise that couples should
be asked for specific and explicit consent. The most
important reason for this is that couples undergo-
ing IVF should be empowered to make voluntary
and informed decisions about the use of their re-
productive materials for research. This is a very
different use for these materials than the one that
couples envisaged when they decided to enter in-
fertility treatment and raises new issues, including
privacy and confidentiality of personal informa-
tion, which must be addressed in an ethically ac-
ceptable manner. Most of the documents investi-
gated also specify who should obtain consent.
Some suggest that this should not be the treating
infertility specialist, nor a member of the research
team. The rationale is to avoid any possible influ-
ence (eg from fear or gratitude) on potential
donors, and to ensure that their consent is truly
voluntary. Within the current Swiss legal frame-
work, however, it is the treating IVF physician
who is supposed to perform the consent proce-
dure (see 2.2). 
The second element arising from the com-
parison of documents is “what” the nature of the
information to be provided to donors should be.
Although some documents are more precise than
others in detailing information that should be
given in order for the couple to make a decision,
there seems to be general agreement on several
items. Donors should be informed, (i) that the
process of deriving hESC effects the ‘destruction’
of embryos, (ii) that they themselves will not ben-
efit from the commercial potential of research
outcomes, (iii) about the specific purposes of the
research protocol or, where the donation is not
limited to specific research purposes, the different
possible categories of research use, so they can se-
lect those they find acceptable. The information
provided to donors should (iv) allow them to un-
derstand the implications of research techniques
that might raise special moral concerns, such as
the production of stem cell lines or the use of
 somatic cell nuclear transfer. Potential donors
should be assured that (v) embryos donated to re-
search will not be used to create a pregnancy, (vi)
their confidentiality will be protected by specific
procedures, (vii) that their decision to give or to
refuse consent will not affect the quality of IVF
treatment they receive, and (viii) that they can
withdraw consent, without giving reasons, up
until the point at which the embryos are actually
used in the research study.
Although several documents consider the
careful timing of the informed choice procedure
to be paramount, there is no general agreement
on what information to provide, at what point and
when consent should be obtained. Some docu-
ments recommend that donors should declare
their willingness to donate or not before starting
IVF. Others advocate a two-phase process: A pre-
liminary decision should be made prior to the col-
lection of gametes for reproductive purposes
and donors should be asked for a final confirma-
tion of this if and when surplus embryos remain
after IVF treatment is completed. With regard to
the timing of information provision, some docu-
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ments suggest that potential donors should be ap-
proached as early as possible, even before starting
the infertility treatment, in order to give couples
adequate time to make their decision. 
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Developing a fair informed choice procedure in Switzerland 
Taking all these considerations and limitations
into account, we propose the following elements
for an appropriate informed choice process within
the current Swiss legal situation.
Informed choice about donating surplus
 embryos 
– Who: In Switzerland, it is the IVF doctor who
informs the couple that IVF has produced a sur-
plus embryo. If there is a surplus embryo, the
doctor needs to explain why the embryo has be-
come surplus and what options are available. If
the couple decides against donation to hESC
research, the surplus embryo cannot be stored
or donated to other couples but will be allowed
to ‘die’. If the couples are interested in the pos-
sibility of donating the surplus embryo to
hESC research, then the doctor moves on to
provide further explanation of what they are
consenting to. We propose that the interna-
tional standard, that aims to avoid conflicts of
interest and provide transparency about the in-
tentions of the treating doctor and the stem cell
scientists, would be ethically preferable here.
That is, the Swiss informed choice procedure
would be improved by removing from the
treating physician the responsibility of ap-
proaching the couple and obtaining consent to
donate.
– What: Couples need to be informed explicitly
that there is no obligation to give their surplus
embryo to research and that a refusal to  donate
to research does not have any effect on their on-
going IVF treatment. They must also be told
that their personal data will be kept confiden-
tial. They must understand that they cannot re-
ceive financial compensation for their donation
and that they will not have any rights to com-
mercial gain from future stem cell lines. Cou-
ples also need to understand the link between
their treatment and research ie they need in-
formation about the research project: Detailed
information sheets about the research and the
research team should be provided to them by
the doctor. They should be able to contact the
research team if they wish. They need to know
that the embryo will be destroyed in the course
of hESC research, that stem cell lines produced
from the embryo may live on for a long time
and be shared between laboratories, that hESC
research is not the same as research to improve
IVF techniques and that they can withdraw
their  consent for donation at any time before
the embryos are actually used in the research
study.
– When: In the interpretation of the current
Swiss legal situation described previously, the
whole process of information and consent has
to be performed within the very narrow time
span between the embryo being identified as
surplus and the legal limit of its use in hESC re-
search (up to six days after cell fusion). Thus the
whole process of informing, reflection, discus-
sion and informed consent is exposed to ex-
treme time pressure. We suggest that the
“when” element of the procedure of informed
choice should be reconsidered and clarified
when the current Swiss regulation is revised.
We consider that the existing procedure in
Switzerland may be interpreted so as to leave
an unacceptably brief time between the provi-
sion of information to donors and the signing
(or not signing) of the informed consent form.
The provision that information about research
donation may only be given after the embryos
have clearly become surplus in the sense of the
law, poses one of the biggest challenges to
maintaining an ethically sound informed
choice procedure within the current Swiss sit-
uation. 
Points to consider in a future revision 
of the Swiss Stem Cell Research Act
1. Avoiding time pressure for the couples
Hence in our view there is one main obstacle
that needs to be removed in the Swiss version of the
IVF-stem cell interface. As we have noted, current
legislation may be interpreted in a way that forces
couples who may want to donate a surplus embryo
for research to act under considerable time pres-
sure. This might in turn hamper their understand-
ing of the issues they are asked to consider, lower
their capability to understand all the relevant as-
pects of the decision, and/or make it harder for
them to consider the implications of their decision.
A perfectly defensible alternative, and one which
would be preferable in our view, is to provide gen-
eral information about the possibility of donating any
surplus embryo before the IVF treatment starts.
Then the couple could think over this eventuality
and be prepared for it should it actually occur. It is
not clear that both partners will have the same ini-
tial opinion about the options. To discuss it between
themselves, and possibly also with friends or rela-
tives if they wish, requires time. Specific details of
the research project for which the embryonic cells
might be used, however, need not be given at this
stage of decision making and the result of the deci-
sion does not need to be disclosed to the IVF doc-
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tor. It is difficult to see how the couple’s consider-
ations of this question could unduly influence the
IVF process if the IVF team does not know the at-
titude of the couple.
2. Transparent interface
A revision of the Stem Cell Research Act
should also pay more attention to differences in
the perspectives and goals of IVF treatment and
stem cell research. Not only should the IVF treat-
ment team not have a vested interest in producing
extra embryos for their own in-house stem cell
laboratory but patients also need to understand
the special role of their treating physician and not
conflate it with the role of the stem cell re-
searchers. If the treating physician is also the
(only) person in charge of the informed choice
procedure for hESC research, the patients’ per-
ception of this distinction will be blurred. In IVF
centres it is possible to charge another person
outside the treatment team eg a research nurse 
or a doctor who is not the treating physician, with
the task of talking to the patients about the impli-
cations of research donation. In some centres it
would also be possible for the patients to meet
one of the stem cell researchers in person. 
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Conclusion
Although one aim of the Swiss Stem Cell Re-
search Act was to avoid the exploitation of couples
undergoing IVF as producers of embryos for stem
cell research, its key concern was to protect em-
bryos from being produced in excess and used for
hESC research instead of being exclusively pro-
duced for pregnancy. The law defines a window
that is narrow enough to avert both of these risks
but still wide enough to allow the use of surplus
embryos, in unavoidable but exceptional circum-
stances, in hESC research. These concerns were
widely discussed at the time of drafting the legis-
lation [6]. However, actual experience of putting
the law into practice has revealed additional con-
cerns, to some of which we have drawn attention
in this paper, that were not predicted and there-
fore perhaps not taken adequately into account. 
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